A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Kotlyar, David S; Osterman, Mark T; Diamond, Robert H; Porter, David; Blonski, Wojciech C; Wasik, Mariusz; Sampat, Sami; Mendizabal, Manuel; Lin, Ming V; Lichtenstein, Gary R

Kotlyar, David S; Osterman, Mark T; Diamond, Robert H; Porter, David; Blonski, Wojciech C; Wasik, Mariusz; Sampat, Sami; Mendizabal, Manuel; Lin, Ming V; Lichtenstein, Gary R.

Affiliation

Kotlyar DS; Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Clin Gastroenterol Hepatol ; 9(1): 36-41.e1, 2011 Jan.

Article in En | MEDLINE | ID: mdl-20888436

Subject(s)

Immunologic Factors/adverse effects; Immunologic Factors/therapeutic use; Inflammatory Bowel Diseases/complications; Inflammatory Bowel Diseases/drug therapy; Liver Neoplasms/epidemiology; Lymphoma, T-Cell/epidemiology; Splenic Neoplasms/epidemiology; Adalimumab; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Humans; Infliximab; Liver Neoplasms/chemically induced; Lymphoma, T-Cell/chemically induced; Purines/adverse effects; Purines/therapeutic use; Splenic Neoplasms/chemically induced; Tumor Necrosis Factor-alpha/antagonists & inhibitors; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Splenic Neoplasms / Inflammatory Bowel Diseases / Lymphoma, T-Cell / Immunologic Factors / Liver Neoplasms Type of study: Systematic_reviews Limits: Humans Country/Region as subject: America do norte Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google